Renal Denervation Devices Market Size

Renal Denervation Devices Market Analysis

The renal denervation devices market is expected to register a CAGR of 36.89% during the forecast period.

• The outbreak of the COVID-19 pandemic impacted the renal denervation devices market as hospitals and healthcare services significantly reduced due to social distancing measures taken by countries across the world. During the COVID-19 outbreak, many medical device manufacturers either delayed or postponed the launch of their devices due to resource and fund crunch, negatively impacting the renal denervation devices market. However, despite these setbacks, rising levels of hypertension coupled with high alcohol consumption during the pandemic may contribute to the market recovery over the foreseeable future. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, the quantity of alcohol sold in 15 US states rose by 4% from January to August 2020 as compared to a year earlier, which could increase the risk of hypertension and stimulate the use of renal denervation devices. Hence, the studied market is anticipated to witness growth in the coming years owing to factors such as a rise in product sales, new product launches, and an increase in hypertension-related health issues.
• Major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. The prevalence of hypertension has been observing a significant rise over the past few years. According to the August 2021 update from the WHO, around 1.28 billion people aged between 30 and 79 years are affected by hypertension globally. An increase in the number of cases of hypertension is expected to create demand for renal denervation devices during the forecast period. Some major reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet.
• Additionally, increasing the patient pool of other chronic diseases like obesity among children and adults will power renal denervation market growth through the forecast period. As per the WHO's statistics, over 39 million children aged below 5 years were overweight in 2021. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension. A rise in the level of daily alcohol consumption will further drive the market growth, as regular drinking may lead to hypertension as it is possible that alcohol may stimulate adrenals to release adrenaline, resulting in increased heart rate, cardiac output, and systolic blood pressure.
• Furthermore, an increase in clinical studies and research and development associated with renal denervation devices and the long-term benefits of renal denervation procedures are anticipated to drive market growth. For instance, as per the article published in April 2022 in Nature journal, more than 80% of Thai patients with resistant hypertension experienced the success of the renal nerve denervation outcome, which was sustained over a longer follow-up without any intervention-related side effects.
• Hence, due to the rise in the prevalence of hypertension and the long-term benefits offered by renal denervation devices, the studied market is anticipated to witness growth in the studied market over the forecast period. However, stringent approval processes for renal denervation devices and reimbursement systems and painful procedures are anticipated to restrain the market growth over the forecast period.